Skip to main content

Table 1 Associations between APOBEC-mutational signature and isoform expression levels of APOBEC3A and APOBEC3B

From: Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types

Cancer typea uc003awn uc011aoc uc011awo
Beta P Beta P Beta P
bladder 0.035 0.08 0.032 0.25 0.130 1.3 × 10− 6
breast 0.085 1.3 × 10− 7 0.159 5.3 × 10− 11 0.053 6.5 × 10− 3
cervical 0.105 3.2 × 10− 5 0.035 0.27 0.076 0.04
lungb 0.076 2.6 × 10− 3 0.097 0.01 0.131 5.2 × 10− 6
lungc 0.021 0.57 −0.072 0.11 −0.037 0.55
head and neck 0.549 1.5 × 10− 4 −0.013 0.52 0.086 2.3 × 10− 3
stomach −0.004 0.88 −0.050 0.40 0.144 8.9 × 10−7
pancreas 0.086 0.15 0.099 0.29 0.076 0.32
thyroid 0.070 0.03 0.043 0.56 0.059 0.12
kidney 0.024 0.52 −0.026 0.77 0.095 0.02
  1. a” Sample size for each cancer type: bladder (N = 388), breast (N = 961), cervical (N = 185), lung adenocarcinoma (N = 475), lung squamous cell carcinoma (N = 178), head and neck (N = 498), stomach (N = 368), pancreas (N = 119), thyroid (N = 485) and kidney (N = 280). “b” and “c” refers to lung adenocarcinoma and lung squamous carcinoma, respectively. A multivariate regression analysis was constructed to include all six isoforms as independent variables and APOBEC-signature mutation as the dependent variable for each cancer type. Multivariate regression analysis was constructed to include all six isoforms as independent variables and APOBEC-signature mutation as the dependent variable for each cancer type. The significance level at P = 0.005, corresponding to a threshold with a Bonferroni-correction of P = 0.05, given 10 tests